A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD.sup.+, or a substance involved in the metabolism of any of these substances.

The invention relates to novel uses of specific mTOR inhibitors as a medicament, in particular for the treatment of X-linked adrenoleukodystrophy (X-ALD). The invention also relates to a method for identifying a compound potentially useful for the treatment and/or prevention of X-ALD.

The invention relates to novel uses of specific mTOR inhibitors as a medicament, in particular for the treatment of X-linked adrenoleukodystrophy (X-ALD). The invention also relates to a method for identifying a compound potentially useful for the treatment and/or prevention of X-ALD.

The invention relates to novel uses of specific mTOR inhibitors as a medicament, in particular for the treatment of X-linked adrenoleukodystrophy (X-ALD). The invention also relates to a method for identifying a compound potentially useful for the treatment and/or prevention of X-ALD.

Provided are methods for the treatment of cancers including leukemias, that utilize combination therapies. In some embodiments, a metal chelator is administered to a patient in combination with a cancer therapy, zinc, selenium, magnesium, and vitamin C to treat the cancer. In some embodiments, increased efficacy of the cancer therapy can be observed, and/or lower dosages of a chemotherapeutic may be administered to the subject as a result of the combination therapy.

Provided are methods for the treatment of cancers including leukemias, that utilize combination therapies. In some embodiments, a metal chelator is administered to a patient in combination with a cancer therapy, zinc, selenium, magnesium, and vitamin C to treat the cancer. In some embodiments, increased efficacy of the cancer therapy can be observed, and/or lower dosages of a chemotherapeutic may be administered to the subject as a result of the combination therapy.

The disclosure provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The disclosure also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The disclosure further provides a method of using the nutritional supplement for treating patients with heart failure.

The disclosure provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The disclosure also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The disclosure further provides a method of using the nutritional supplement for treating patients with heart failure.

The disclosure provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The disclosure also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The disclosure further provides a method of using the nutritional supplement for treating patients with heart failure.

The present invention provides a composition for improving mind-concentration, characterized in that the composition comprises theanine; and a method of improving mind-concentration comprising administering theanine to an individual.